Clinical Trials Logo

Severe Asthma clinical trials

View clinical trials related to Severe Asthma.

Filter by:

NCT ID: NCT03608566 Recruiting - Severe Asthma Clinical Trials

Russian Severe Asthma Registry

RSAR
Start date: March 30, 2018
Phase:
Study type: Observational [Patient Registry]

The Russian Severe Asthma Registry is a Russian initiative to collect anonymous long-term evidence for patients with severe asthma in Russia

NCT ID: NCT03476109 Recruiting - Severe Asthma Clinical Trials

Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.

PREDICTUMAB
Start date: May 10, 2019
Phase: Phase 4
Study type: Interventional

Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies.

NCT ID: NCT03435237 Recruiting - Severe Asthma Clinical Trials

Phenotyping Asthma for Bronchial Thermoplasty

Start date: May 10, 2021
Phase:
Study type: Observational

This study will evaluate a new imaging technology, called optical coherence tomography (OCT) to examine the asthmatic airways before and after bronchial thermoplasty, which is a new treatment option for severe asthmatic patients. The aim of this study is to learn more about how airways respond to this new treatment. In the future the investigators hope OCT will aid clinicians in the initial assessment, management and long-term follow up of patients receiving bronchial thermoplasty.

NCT ID: NCT03377920 Recruiting - COPD Clinical Trials

Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.

Start date: October 12, 2017
Phase: N/A
Study type: Interventional

The main aim is to study correlations between Peak inspiratory flow measured during a spirometry (PIFspiro) and Peak inspiratory flow measured over a pre-set resistance (PIFresist) in COPD patients and severe asthma patients. PIFresist will be measured using 5 different resistances, representing all DPI's relevant for the treatment of obstructive lung diseases. If this shows a distinct relationship between PIFspiro and PIFresist, PIFspiro cut-off points will be sought in an attempt to predict which patients are likely to be able to produce optimal flows for DPI use. If successful, this will make the actual measurement of PIFresist redundant in clinical practice. Also the relationship between PIFresist and device internal resistance in addition to PIFspiro (which corresponds to a very low resistance) will be examined.